Abstract

Background Exhaled breath temperature (EBT) has been shown to reflect airway inflammation as well as increased vascularization, both involved in the pathogenesis of lung cancer. The aim of this study was to look for evidence that continuous EBT monitoring by such a device may help the early detection of relapse of lung cancer in patients with NSCLC who have been subjected to surgery with radical intent. Case Series. We included 11 subjects, who had been subjected to lung resection with radical intent for NSCLC in a prospective observational study. All patients received individual devices for EBT measurement and used them daily for 24 months after surgery. Subjects were also followed up by means of regular standard-of-care clinical and radiologic monitoring for lung cancer at four intervals separated by 6 months (T0, T1, T2, T3, and T4). In 5 patients, relapse of lung cancer was documented by means of lung biopsies. All of them recorded an elevation of their EBT at least one-time interval (T1), corresponding to 6 months, before the relapse was diagnosed at T4. The individual EBT graphs over time differed among these patients, and their mean EBT variability increased by +4% towards the end of 24 months of monitoring. By contrast, patients without a relapse did not document an elevation of their EBT and their variability decreased by -1.4%. Conclusions Our pilot study provided evidence that continuous EBT monitoring can help in the early detection of lung cancer relapse.

Highlights

  • Lung cancer is still the leading cause of cancer death worldwide

  • The aim of this study was to look for evidence that continuous Exhaled breath temperature (EBT) monitoring by such a device may help the early detection of relapse of lung cancer in patients with non-small-cell lung cancer (NSCLC) who have been subjected to surgery with radical intent

  • Our pilot study provided evidence that continuous EBT monitoring can help in the early detection of lung cancer relapse

Read more

Summary

Introduction

Lung cancer is still the leading cause of cancer death worldwide. Global numbers are continuously rising despite an ongoing small decline in the Western world [1].Tumor-node-metastasis (TNM) clinical staging system is considered the milestone for predicting prognosis, and the surgical removal of the tumor (anatomical resection with systematic nodal dissection) is the standard treatment for operable patients [2].BioMed Research InternationalPatients affected by non-small-cell lung cancer (NSCLC), treated with a surgical radical intent, have a significantly increased risk to develop a lung cancer relapse or a second primary lung tumor. In a large group of patients who underwent surgical resection, the standardized follow-up revealed that during the first 4 years after surgery, the risk of recurrence ranges from 6% to 10% per person per year, but thereafter, it decreases to 2% [4]. The aim of this study was to look for evidence that continuous EBT monitoring by such a device may help the early detection of relapse of lung cancer in patients with NSCLC who have been subjected to surgery with radical intent. Our pilot study provided evidence that continuous EBT monitoring can help in the early detection of lung cancer relapse

Objectives
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call